These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26878791)

  • 1. Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Nutr Biochem; 2016 Feb; 28():140-6. PubMed ID: 26878791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of Parkinson's disease.
    Leem E; Nam JH; Jeon MT; Shin WH; Won SY; Park SJ; Choi MS; Jin BK; Jung UJ; Kim SR
    J Nutr Biochem; 2014 Jul; 25(7):801-6. PubMed ID: 24797334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
    Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
    Cheng L; Chen L; Wei X; Wang Y; Ren Z; Zeng S; Zhang X; Wen H; Gao C; Liu H
    J Neuroinflammation; 2018 Aug; 15(1):243. PubMed ID: 30157869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
    Hernandes MS; Santos GD; Café-Mendes CC; Lima LS; Scavone C; Munhoz CD; Britto LR
    PLoS One; 2013; 8(9):e75532. PubMed ID: 24086556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
    Kumari R; Kumar JB; Luthra PM
    Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
    Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
    Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
    Stenslik MJ; Potts LF; Sonne JW; Cass WA; Turchan-Cholewo J; Pomerleau F; Huettl P; Ai Y; Gash DM; Gerhardt GA; Bradley LH
    J Neurosci Methods; 2015 Aug; 251():120-9. PubMed ID: 25999268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
    Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
    Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naringin: a protector of the nigrostriatal dopaminergic projection.
    Jung UJ; Leem E; Kim SR
    Exp Neurobiol; 2014 Jun; 23(2):124-9. PubMed ID: 24963276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective Effects of Tanshinone I Against 6-OHDA-Induced Oxidative Stress in Cellular and Mouse Model of Parkinson's Disease Through Upregulating Nrf2.
    Jing X; Wei X; Ren M; Wang L; Zhang X; Lou H
    Neurochem Res; 2016 Apr; 41(4):779-86. PubMed ID: 26537816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naringin Exhibits Neuroprotection Against Rotenone-Induced Neurotoxicity in Experimental Rodents.
    Garabadu D; Agrawal N
    Neuromolecular Med; 2020 Jun; 22(2):314-330. PubMed ID: 31916219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.